Quantcast

Latest Channelopathy Stories

2008-09-03 09:00:46

WARRINGTON, Pa., Sept. 3, 2008 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announces that its proprietary, aerosolized KL-4 surfactant has been selected for a Phase 2a clinical trial in patients with Cystic Fibrosis (CF). The trial is being conducted as an investigator-initiated study under the direction of Dr. Scott H. Donaldson at The University of North Carolina and is funded primarily through a grant provided by the Cystic Fibrosis Foundation. The trial is designed as...

2008-09-03 09:00:46

LINCOLN, R.I., Sept. 3 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of sight-saving therapeutics for chronic retinal diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designations for NT-501 for the treatment of visual loss in two indications -- retinitis pigmentosa (RP) and the dry form of age-related macular degeneration (dry AMD). NT-501 is an intraocular, cell containing...

2008-08-30 09:00:20

What was your first experience of cystic fibrosis? I have two grandsons, now in their twenties, who were diagnosed at birth. It's a shock when you hear that news and you don't really know anything about the disease. When you are told, point-blank, they may not live beyond their teenage years, it's frightening. From the day it's diagnosed, you know you're living with a timebomb. What do you now know about the disease? It's a genetic condition which affects internal organs, especially the...

2008-08-22 09:01:11

Kamada has completed a Phase II study with aerosolized alpha-1 antitrypsin, delivered via an optimized eFlow platform nebulizer from PARI Pharma, in cystic fibrosis. The trial aimed at validating the safety of the product in cystic fibrosis patients and to assess its potential influence on lung inflammation. Preliminary results indicate that the product has an excellent safety profile; final data should be available by year-end 2008, said Kamada. The trial, which was a double-blind,...

2008-08-19 06:00:16

Research and Markets (http://www.researchandmarkets.com/research/8e04b4/cystic_fibrosis_w) has announced the addition of Decision Resources, Inc.'s new report "Cystic Fibrosis: Will New Agents Emerge as First-Line Therapies?" to their offering. The cystic fibrosis (CF) market is poised for significant change. The next generation of CF treatments all target the central mechanism responsible for organ damage in CF. These agents, as one thought leader states, "represent the closest we have...

2008-07-14 09:00:14

WALTHAM, Mass., July 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that in 2007, the United States market for the treatment of pulmonary symptoms of cystic fibrosis reached $397 million, reflecting primarily sales of Genentech/Roche's Pulmozyme and Novartis's antibiotic Tobi. Sales of these agents have helped the market grow at more than 15 percent annually since 2000. That growth however,...

2008-07-09 12:00:49

HUNTINGTON BEACH, Calif., July 9 /PRNewswire-USNewswire/ -- Amazingly, surfers have unknowingly held a key to prolonging the lifespan and quality of life for people with cystic fibrosis (CF), a fatal genetic disease that causes the body to produce thick, sticky mucus, which clogs the lungs and leads to life-threatening lung infections. Several years ago, doctors in Australia noticed young surfers with cystic fibrosis had significantly healthier lungs. The doctors determined that inhaling...

2008-07-08 09:01:11

FoldRx Pharmaceuticals, Inc. (FoldRx) today announced that it has discovered a series of novel drug prototypes that have shown potential in vitro to correct the protein-folding defect associated with cystic fibrosis (CF). The discovery, made through a research collaboration announced last year with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, may pave the way to novel drugs capable of repairing the protein misfolding...

2008-06-30 15:03:02

Case Western Reserve University School of Medicine, in collaboration with Copernicus Therapeutics, Inc. and Polgenix, Inc., was selected to receive $3.9 million in funding from the Ohio Biomedical Research Commercialization Program (BRCP) as awarded by Lieutenant Governor Lee Fisher, Chair of the Ohio Third Frontier Commission. The BRCP awards grants that support Ohio-based biomedical and biotechnology research leading to commercialization and long-term improvements to the health of...

2008-06-30 09:02:20

Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced positive results from an open-label, two week efficacy and safety study of its once daily inhaled liposomal ciprofloxacin in patients with cystic fibrosis (CF). The study conducted at leading CF centers in Australia and New Zealand enrolled a total of 22 patients. The primary efficacy endpoint in this Phase 2 study was the change from baseline in the sputum Pseudomonas Aeruginosa colony forming units (CFU), an objective...


Latest Channelopathy Reference Libraries

Cystic Fibrosis
2013-07-19 15:03:45

Cystic fibrosis, also called mucoviscidosis, is an autosomal recessive genetic disorder of the viscous secretions in the body. In turn, it effects the lungs, pancreas, liver, and intestines, as well as all other exocrine glands in the body. The most common genetic mutation that causes CF is a deletion of three nucleotides that results in a loss of phenylalanine, an amino acid at the 508th position on the protein. It should be noted, however, that there are over a thousand other mutations that...

More Articles (1 articles) »
Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related